Gilead Sciences, Inc. (NASDAQ: GILD ) continues to churn out nothing but fantastic news with its experimental oral hepatitis-C drug, Sofosbuvir. In a mid-stage combination trial with Johnson & Johnson (NYSE:JNJ ) and Medivir 's Simeprevir, the combo cleared all detectable levels of the virus in 100% of genotype 1 patients — the most common form of hepatitis-C. With no adverse events reported, Sofosbuvir once again proved to the biotech community that it could be the standalone and combination drug of choice in oral hepatitis-C care. Pharmaceutical company Impax Laboratories Inc (NASDAQ: IPXL ) was crushed on Tuesday, after it provided an update to investors regarding the FDA's complete response letter on idiopathic Parkinson's disease drug Rytary. According to the update, the FDA cited 12 points of concern with its Hayward, Calif., facility, of which three were repeat violations from a warning letter sent to the company in 2011.